Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1955 1
1956 1
1957 1
1958 1
1959 2
1960 1
1961 1
1962 3
1963 1
1964 3
1965 2
1967 2
1968 2
1969 1
1970 7
1971 1
1972 2
1973 2
1974 4
1975 3
1976 1
1977 5
1978 2
1979 2
1980 2
1986 1
1992 4
1993 1
1994 6
1995 2
1996 2
1997 2
1998 1
2000 3
2001 4
2002 3
2003 1
2004 4
2006 2
2007 5
2008 1
2011 2
2012 1
2013 1
2014 2
2015 2
2016 4
2017 3
2018 3
2019 4
2020 2
2021 7
2022 4
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Investigators; Ghert M, Schneider P, Guyatt G, Thabane L, Vélez R, O'Shea T, Randall RL, Turcotte R, Wilson D, Wunder JS, Baptista AM, Cheng EY, Doung YC, Ferguson PC, Giglio V, Hayden J, Heels-Ansdell D, Khan SA, Sampath Kumar V, McKay P, Miller B, van de Sande M, Zumárraga JP, Bhandari M. Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Investigators, et al. JAMA Oncol. 2022 Mar 1;8(3):345-353. doi: 10.1001/jamaoncol.2021.6628. JAMA Oncol. 2022. PMID: 34989778 Free PMC article. Clinical Trial.
Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database.
Gosselin L, Vilcu AM, Souty C, Steichen O, Launay T, Conte C, Saint-Salvi B, Turbelin C, Sarazin M, Blanchon T, Hanslik T, Lapeyre-Mestre M, Rossignol L. Gosselin L, et al. Eur J Clin Pharmacol. 2023 Jul;79(7):937-945. doi: 10.1007/s00228-023-03501-8. Epub 2023 May 15. Eur J Clin Pharmacol. 2023. PMID: 37184597
133 results